NCT03055338View on ClinicalTrials.gov

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

January 9, 2018

Study Completion Date

January 9, 2018

Conditions
Schizophrenia, Acute Episode
Interventions
DRUG

MK-8189

Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)

DRUG

Risperidone

Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)

DRUG

Placebo matching MK-8189

Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.

DRUG

Placebo matching risperidone

Oral placebo capsule(s) matching the risperidone capsule, administered QD.

Trial Locations (28)

10019

Radiant Research -CliniLabs ( Site 0037), New York

20877

CBH Health, LLC ( Site 0022), Gaithersburg

30328

Radiant Research - Atlanta ( Site 0008), Atlanta

30331

Atlanta Center For Medical Research ( Site 0056), Atlanta

32810

Aspire Health Partners ( Site 0016), Orlando

33021

Larkin Community Hospital Behavioral Health Services ( Site 0020), Hollywood

33334

Clinical Research Centers of America, LLC ( Site 0038), Oakland Park

39232

Precise Research Centers ( Site 0018), Flowood

45417

Midwest Clinical Research Unit ( Site 0041), Dayton

60169

Alexian Center for Psychiatric Research ( Site 0015), Hoffman Estates

63128

Psych Care Consultants Research ( Site 0025), St Louis

63141

St. Louis Clinical Trials, LLC ( Site 0012), St Louis

70629

Lake Charles Clinical Trials, LLC ( Site 0040), Lake Charles

72211

Woodland International Research Group, LLC ( Site 0001), Little Rock

72758

Woodland Research Northwest, LLC ( Site 0014), Rogers

75080

Pillar Clinical Research, LLC ( Site 0004), Richardson

75115

InSite Clinical Research ( Site 0033), DeSoto

89102

Altea Research Institute ( Site 0017), Las Vegas

90502

Collaborative Neuroscience Network, LLC ( Site 0046), Torrance

90660

CNRI - Los Angeles, LLC ( Site 0026), Pico Rivera

90703

Comprehensive Clinical Development ( Site 0049), Cerritos

90706

CITRIALS ( Site 0013), Bellflower

91206

Behavioral Research Specialists, LLC ( Site 0006), Glendale

91403

Schuster Medical Research Institute ( Site 0032), Sherman Oaks

91945

Synergy East ( Site 0003), Lemon Grove

92103

Artemis Institute for Clinical Research ( Site 0027), San Diego

92845

Collaborative Neuroscience Network, LLC ( Site 0057), Garden Grove

92868

NRC Research Institute ( Site 0043), Orange

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03055338 - An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) | Biotech Hunter | Biotech Hunter